Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | NAE1 | Q13564 | 14/20 | 0.44 |
| ▸ | UBA3 | Q8TBC4 | 14/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456613 | 1.00 | EGFR (0.48) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL22401411 | 0.88 | EGFR (0.44) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL23456264 | 0.88 | EGFR (0.44) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL27250614 | 0.82 | EGFR (0.49) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL23456099 | 0.81 | NAE1 (0.47) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL30164347 | 0.81 | NAE1 (0.47) | EGFRERBB3ADORA3NAE1UBA3 | |
| SCHEMBL23455989 | 0.80 | NAE1 (0.40) | NAE1UBA3 | |
| SCHEMBL22401427 | 0.77 | NAE1 (0.36) | NAE1UBA3 | |
| SCHEMBL23456069 | 0.77 | NAE1 (0.36) | NAE1UBA3 | |
| SCHEMBL23455980 | 0.75 | SLC6A11 (0.35) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | EGFR 1818/4885ERBB3 3787/4885ADORA3 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.